Microdosing comes up in my clinic more often than full sessions do, and almost always in the same sentence as a medication: "I've been thinking about microdosing instead of the Lexapro." I want to answer that sentence properly, as a psychiatric nurse practitioner who prescribes the Lexapro, because the honest answer has a legal half, an evidence half, and a safety half, and the forum version gets all three wrong.
The legal half, briefly
In Colorado, adults 21 and over may possess, grow, and share psilocybin mushrooms for personal use without criminal penalty, and no one may sell them. That is the whole of what Proposition 122 did for microdosing. The regulated program, with its licensed facilitators and healing centers, is built around supervised sessions; nothing in it covers a take-home product or a daily capsule. In Oregon there is no personal-use allowance at all outside the licensed service centers. Federally, psilocybin remains Schedule I, which matters for anyone with a security clearance, a federal job, a commercial driver's license, or an employer that tests. The Colorado statute does not protect a positive test.
The evidence half, which is the part people skip
The claims made for microdosing are large: better mood, sharper focus, less anxiety, an antidepressant without the side effects. The controlled research is small and consistently sobering. Two double-blind, placebo-controlled trials published in 2026 found that psilocybin microdosing did not significantly change behavioral or subjective measures compared with placebo, and that participants could not reliably tell which they had taken. That is not proof that nothing is happening; it is strong evidence that much of what people feel is expectation, a real effect and a fragile one. When a patient tells me microdosing lifted their mood, I believe them; belief is still not a treatment plan for a major depressive disorder.
The safety half, from the prescriber's chair
Small doses do not mean no interactions. Psilocybin acts on the same serotonergic system an SSRI does; most of the published concern is about dampening, but daily low doses on top of an antidepressant have not been studied well enough to reassure me. Lithium is a separate matter, serious enough that Colorado's facilitator rules forbid even supervised sessions for anyone taking it without a clinician's review. The part that worries me most is the person who tapers an antidepressant alone to make room for a microdose. Discontinuation symptoms arrive, mood slips, and the microdose gets the blame or the credit for a change it did not cause. If you are going to do this anyway, tell your prescriber, so that what happens next can be read correctly.
What I offer instead of a capsule
Most people who ask about microdosing are describing a medication that is not working well enough or a side effect they have stopped mentioning. Both are solvable in medication management: a ninety-minute evaluation, pharmacogenomic testing when it would change the choice, a dose or drug changed on purpose, follow-ups every two to four weeks. For anxiety that a microdose is meant to quiet, therapy has decades of evidence behind it. For a depression that has outlasted two proper trials, Spravato and off-label, medically supervised ketamine-assisted psychotherapy are the options with real data. And for the person genuinely curious about psilocybin rather than looking for an exit from a prescription, a single legal session at a licensed center, with clinical preparation and integration around it, is at least the version the research has studied. The facilitator's view of microdosing is in the MycoMuse journal.
If the sentence that brought you here had a medication in it, bring the whole sentence to a clinician. The first conversation at MindMorph is a free consultation through the contact page, by secure video in Colorado and Oregon.
This writing is education, not legal or medical advice. MindMorph does not provide, administer, or facilitate psilocybin in any dose; legal supervised access exists only through Colorado's and Oregon's licensed centers, for adults 21 and over. Never stop or change a prescribed medication without the prescriber who manages it.
Sources
- Colorado DORA, Natural Medicine Health Act
- Colorado Department of Revenue, Natural Medicine Division
- Prochazkova et al., Neuropharmacology 2026: two double-blind placebo-controlled trials of psilocybin microdosing
- Colorado facilitator rules, 4 CCR 755-1, Rule 2.2(A)(7) on lithium and antipsychotics
- Johns Hopkins research on antidepressants and attenuated psilocybin response (PubMed)
Questions this post answers
Personal possession, growing, and sharing by adults 21 and over is decriminalized under state law; sale is not, and the regulated program covers supervised sessions only, with no take-home product. Federal law still lists psilocybin as Schedule I, so employer drug tests, federal jobs, security clearances, and commercial licenses are unaffected by the Colorado statute. Oregon has no personal-use allowance outside licensed service centers.
The controlled evidence says not measurably. Two double-blind, placebo-controlled trials published in 2026 found no significant difference from placebo on behavioral or subjective measures, and participants could not reliably tell what they had taken. People do report feeling better, and expectation is a real effect, but it is not a treatment plan for a diagnosed disorder. Bring the symptom to a clinician instead.
Talk to your prescriber before anything else. Psilocybin and SSRIs act on the same serotonergic system, and daily low doses on top of an antidepressant have not been studied carefully. Lithium is serious enough that Colorado forbids even supervised sessions for anyone taking it without a clinician's review. Never taper a medication on your own to make room for a microdose.
Usually the thing the microdose was standing in for. Medication management with a ninety-minute evaluation and pharmacogenomic testing when useful; therapy for anxiety; Spravato or off-label, medically supervised ketamine-assisted psychotherapy for depression that has resisted two proper trials. For genuine interest in psilocybin, a single legal supervised session with clinical preparation and integration is the studied version. MindMorph provides no psilocybin.
